G1 phase accumulation induced by UCN-01 is associated with dephosphorylation of Rb and CDK2 proteins as well as induction of CDK inhibitor p21/Cip1/WAF1/Sdi1 in p53-mutated human epidermoid carcinoma A431 cells

Cancer Research

Volumn 57, Issue 8, 1997, Pages 1495-1501

  Akiyama, Tadakazu ^a   Yoshida, Tetsuo ^a   Tsujita, Tetsuya ^a   Shimizu, Makiko ^a   Mizukami, Tamio ^a   Okabe, Masami ^a   Akinaga, Shiro ^a  

^a KYOWA HAKKO KOGYO CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

7 HYDROXYSTAUROSPORINE; PROTEIN KINASE C; 7-HYDROXYSTAUROSPORINE; ALKALOID; ANTINEOPLASTIC AGENT; CDK2 PROTEIN, HUMAN; CDKN1A PROTEIN, HUMAN; CELL CYCLE PROTEIN; CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE INHIBITOR 1A; CYCLIN DEPENDENT KINASE INHIBITOR 1B; CYCLINE; DRUG DERIVATIVE; MESSENGER RNA; MICROTUBULE ASSOCIATED PROTEIN; PROTEIN SERINE THREONINE KINASE; RETINOBLASTOMA PROTEIN; STAUROSPORINE; TUMOR SUPPRESSOR PROTEIN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CELL CYCLE G1 PHASE; CONCENTRATION RESPONSE; DEPHOSPHORYLATION; DRUG EFFECT; ENZYME ACTIVITY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN SYNTHESIS REGULATION; SQUAMOUS CELL CARCINOMA; CELL CULTURE; DRUG ANTAGONISM; GENETICS; METABOLISM; PHOSPHORYLATION;

ALKALOIDS; ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; CDC2-CDC28 KINASES; CELL CYCLE PROTEINS; CYCLIN-DEPENDENT KINASE 2; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLIN-DEPENDENT KINASE INHIBITOR P27; CYCLIN-DEPENDENT KINASES; CYCLINS; G1 PHASE; HUMANS; MICROTUBULE-ASSOCIATED PROTEINS; PHOSPHORYLATION; PROTEIN-SERINE-THREONINE KINASES; RETINOBLASTOMA PROTEIN; RNA, MESSENGER; STAUROSPORINE; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEINS;

EID: 0030615323     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (60)

1. Takahashi, I., Kobayashi, E., Asano, K., Yoshida, M., and Nakano, H. UCN-01, a selective inhibitor of protein kinase C from Streptomyces. J. Antibiot., 40: 1782-1784, 1987.
2. Akinaga, S., Gomi, K., Morimoto, M., Tamaoki, T., and Okabe, M. Antitumor activity of UCN-01, a selective inhibitor of protein kinase C, in murine and human tumor models. Cancer Res. 51: 4888-4892, 1991.
3. Seynaeve, C. M., Stetler-Stevenson, M., Sebers, S., Kaur, G., Sausville, E. A., and Worland, P. J. Cell cycle arrest and inhibition by the protein kinase antagonist UCN-01 in human breast carcinoma cells. Cancer Res., 53: 2081-2086, 1993.
4. Akinaga, S., Nomura, K., Gomi, K., and Okabe, M. Enhancement of antitumor activity of mitomycin C in vitro and in vivo by UCN-01, a selective inhibitor of protein kinase C. Cancer Chemother. Pharmacol., 32: 183-189, 1993.
5. Wang, Q., Worland, P. J., Clark, J. L., Carlson, B. A., and Sausville, E. A. Apoptosis in 7-hydroxystaurosporine-treated T lymphoblasts correlates with activation of cyclin-dependent kinase 1 and 2. Cell Growth & Differ., 6: 927-936, 1995.
6. Pollack, I. F., Kawecki, S., and Lazo, J. S. Blocking of glioma proliferation in vitro and in vivo and potentiating the effects of BCNU and cisplatin: UCN-01, a selective protein kinase inhibitor. J. Neurosurg., 84: 1024-1032, 1996.
7. Akinaga, S., Nomura, K., Gomi, K., and Okabe, M. Effect of UCN-01, a selective inhibitor of protein kinase C, on the cell-cycle distribution of human epidermoid carcinoma A431 cells. Cancer Chemother. Pharmacol., 33: 273-280, 1994.
8. Akinaga, S., Nomura, K., Gomi, K., and Okabe, M. Diverse effects of indolocarbazole compounds on the cell cycle progression of ras-transformed rat fibroblast cells. J. Antibiot., 46: 1767-1771, 1993.
9. Kawakami, K., Futami, H., Takahara, J., and Yamaguchi, K. UCN-01, 7-hydroxyl-staurosporine, inhibits kinase activity of cyclin-dependent kinase and reduces the phosphorylation of the retinoblastoma susceptibility gene product in an A549 human lung carcinoma cell line. Biochem. Biophys. Res. Commun., 219: 778-783, 1996.
10. Akinaga, S., Nomura, K., Gomi, K., and Okabe, M. Synergistic antitumor effect of UCN-01, a protein kinase (C) inhibitor, combined with various anti-cancer agents. Proc. Am. Assoc. Cancer Res., 29: 3072, 1993.
11. 2-checkpoint inhibitor. Clin. Cancer Res., 2: 791-797, 1996.
12. 2 checkpoint function in cancer cells with erupted p53. Proc. Am. Assoc. Cancer Res., 37: 2871, 1996.
13. MacLachlan, T. K., Sang, N., and Giordano, A. Cyclins, cyclin-dependent kinases and CDK inhibitors: implications in cell cycle control and cancer. Eukaryolic Gene Expression, 5: 127-156, 1995.
14. Fisher, R. P., and Morgan, D. O. A novel cyclin associates with MO15/CDK7 to form the CDK-activating kinase. Cell, 78: 713-724, 1994.
15. Weinberg, R. A. The retinoblastoma protein and cell cycle control. Cell, 81: 323-330, 1995.
16. La Thangue, N. B. DRTF1/E2F: an expanding family of heterodimeric transcription factors implicated in cell-cycle control. Trends Biochem. Sci., 19: 108-114, 1994.
17. Sherr, C. J., and Roberts, J. M. Inhibitors of mammalian G1 cyclin-dependent kinases. Genes Dev., 9: 1149-1163, 1995.
18. Aprelikova, O., Xiong, Y., and Liu, E. T. Both p16 and p21 families of cyclin-dependent kinase (CDK) inhibitors block the phosphorylation of cyclin-dependent kinases by the CDK-activating kinase. J. Biol. Chem., 270: 18195-18197, 1995.
19. Waga, S., Hannon, G. J., Beach, D., and Stillman, B. The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA. Nature (Lond.), 369: 574-578, 1994.
20. Terada, N., Lucas, J. J., Szepesi, A., Franklin, R. A., Domenico, J., and Gelfand, E. W. Rapamycin blocks cell cycle progression of activated T cells prior to events characteristic of middle to late G1 phase of the cell cycle. J. Cell. Physiol., 154: 7-15, 1993.
21. 1 arrest at two points: effect on retinoblastoma protein phosphorylation and cyclin-dependent kinase 2 in normal and transformed cells. Cancer Res., 54: 5959-5963, 1994.
22. Schnier, J. B., Nishi, K., Goodrich, D. W., and Bradbury, E. M. G1 arrest and down-regulation of cyclin E/cyclin-dependent kinase 2 by the protein kinase inhibitor staurosporine are dependent on the retinoblastoma protein in the bladder carcinoma cell line 5637. Proc. Natl. Acad. Sci. USA, 93: 5941-5946, 1996.
23. Watts, C. K. W., Brady, A., Sarcevic, B., deFazio, A., Musgrove, E. A., and Sutherland, R. L. Antiestrogen inhibition of cell cycle progression in breast cancer cells is associated with inhibition of cyclin-dependent kinase activity and decreased retinoblastoma protein phosphorylation. Mol. Endocrinol., 9: 1804-1813, 1995.
24. Koff, A., Ohtsuki, M., Polyak, K., Roberts, R. A., and Massagué, J. Negative regulation of G1 in mammalian cells: inhibition of cyclin E-dependent kinase by TGF-β. Science (Washington DC), 260: 536-539, 1993.
25. Resnitzky, D., Tiefenbrun, N., Berissi, H., and Kimchi, A. Interferons and interleukin 6 suppress phosphorylation of the retinoblastoma protein in growth-sensitive hematopoietic cells. Proc. Natl. Acad. Sci. USA, 89: 402-406, 1992.
26. Jeoung, D-I., Tang, B., and Sonenberg, M. Effects of tumor necrosis factor-α on antimitogenicity and cell cycle-related proteins in MCF-7 cells. J. Biol. Chem., 270: 18367-18373, 1995.
27. 1 arrest and apoptosis. Cancer Res., 54: 1169-1174, 1994.
28. Li, C-Y., Suardet, L., and Little, J. B. Potential role of WAF1/Cip1/p21 as a mediator of TGF-β cytoinhibitory effect. J. Biol. Chem., 270: 4971-4974, 1995.
29. Datto, M. B. Li, Y., Panus, J. F., Howe, D. J., Xiong, Y., and Wang, X-F. Transforming growth factor β induces the cyclin-dependent kinase inhibitor p21 through a p53-independent mechanism. Proc. Natl. Acad. Sci. USA, 92: 5545-5549, 1995.
30. Shao, Z-M., Dawson, M. I., Li, X. S., Rishi, A. K., Sheikh, M. S., Han, Q-X., Ordonez, J. V., Shroot, B., and Fontana. J. A. p53 independent G0/G1 arrest and apoptosis induced by a novel retinoid in human breast cancer cells. Oncogene, 11: 493-504, 1995.
31. Jiang, H., Lin, J., Su, Z-Z., Collart, F. R., Huberman, E., and Fischer, P. B. Induction of differentiation in human premyelocytic HL-60 leukemia cells activates p21, WAF1/CIP1, expression in the absence of p53. Oncogene, 9: 3397-3406, 1994.
32. Zhang, W., Grasso, L., McClain, C. D., Gambel, A. M., Cha, Y., Travali, S., Deisseroth, A. B., and Mercer, W. E. p53-independent induction of WAF1/CIP1 in human leukemia cells is correlated with growth arrest accompanying monocyte/macrophage differentiation. Cancer Res., 55: 668-674, 1995.
33. Kip1, a cyclin-dependent kinase inhibitor and a potent mediator of extracellular antimitogenic signals. Cell, 78: 59-66, 1994.
34. Kip1) of cyclin-dependent kinase 4 activation. Cell, 79: 487-496, 1994.
35. Hengst, L., Dulic, V., Slingerland, J. M., Lees, E., and Reed, S. I. A cell cycle-regulated inhibitor of cyclin-dependent kinases. Proc. Natl. Acad. Sci. USA, 91: 5291-5295, 1994.
36. Kip1 cyclin-dependent inhibitor prevented by rapamycin. Nature (Lond.), 372: 570-573, 1994.
37. Wang, Q. M., Jones, J. B., and Studzinski, G. P. Cyclin-dependent kinase inhibitor p27 as a mediator of the G1-S phase block induced by 1,25-dihydroxyvitamin D3 in HL-60 cells. Cancer Res., 56: 264-267, 1996.
38. Pagano, M., Pepperkok, R., Verde, F., Ansorge, W., and Draetta, G. Cyclin A is required at two points in the human cell cycle. EMBO J., 11: 961-971, 1992.
39. Rosenblatt, J., Gu, Y., and Morgan, D. O. Human cyclin-dependent kinase 2 is activated during the S and G2 phases of the cell cycle and associates with cyclin A. Proc. Natl. Acad. Sci. USA, 89: 2824-2828, 1992.
40. Laemmli, U. K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature (Lond.), 227: 580-685, 1970.
41. El-Deiry, W. S., Tokino, T., Velculescu, V. E., Levy, D. B., Parsons, R., Trent J. M., Lin, D., Mercer, W. E., Kinzler, K. W., and Vogelstein, B. WAF1, a potential mediator of p53 tumor suppression. Cell, 75: 817-825, 1993.
42. DeCaprio, J., Ludlow, J. W., Lynch, D., Furukawa, Y., Griffin, J., Piwnica-Worms, H., Huang, C. M., and Livingston, D. M. The product of the retinoblastoma susceptibility gene has properties of a cell cycle regulatory element. Cell, 58: 1085-1095, 1989.
43. Buchkovich, K., Duffy, L. A., and Harlow, E. The retinoblastoma protein is phosphorylated during specific phases of the cell cycle. Cell, 58: 1097-1105, 1989.
44. Chen, P. L., Scully, P., Shew, J. Y., Wang, J. Y. J., and Lee, W. H. Phosphorylation of the retinoblastoma gene product is modulated during the cell cycle and cellular differentiation. Cell, 58: 1193-1198, 1989.
45. Sewing, A., Ronicke, V., Burger, C., Funk, M., and Muller, R. Alternative splicing of human cyclin E. J. Cell Sci., 107: 581-588, 1994.
46. Ohtsubo, M., Theodoras, A. M., Schumacher, J., Roberts, J. M., and Pagano, M. Human cyclin E, a nuclear protein essential for the G1-to-S phase transition, Mol. Cell. Biol., 15: 2612-2624, 1995.
47. Gu, Y., Rosenblau, J., and Morgan, D. O. Cell cycle regulation of CDK2 activity by phosphorylation of Thr160 and Tyr15. EMBO J., 11: 3995-4005, 1992.
48. Steegenga, W. T., Van Laar, T., Shvarts, A., Terleth, C. Van der Eb, A. J., and Jochemsen, A. G. Distinct modulation of p53 activity in transcription and cell-cycle regulation by the large (54 kDa) and small (21 kDa) adenovirus E1B proteins. Virology, 272: 543-554, 1995.
49. Cip1/WAF1/CDK2/PCNA complex by epidermal growth factor receptor activation mediates ligand-induced A431 cell growth inhibition. J. Cell Biol., 131: 235-242, 1995.
50. Gong, J., Traganos, F., and Darzynkiewicz, Z. Staurosporine blocks cell progression through G1 between the cyclin D and cyclin E restriction points. Cancer Res., 54: 3136-3139, 1994.
51. Crissman, H. A., Gadbois, D. M., Tobey, R. A., and Bradbury, E. M. Transformed mammalian cells are deficient in kinase-mediated control of progression through the G1 phase of the cell cycle. Proc. Natl. Acad. Sci. USA, 88: 7580-7584, 1991.
52. Bruno, S., Ardelt, B., Skierski, J. S., Traganos, F., and Darzynkiewicz, Z. Different effects of Staurosporine, an inhibitor of protein kinases, on the cell cycle and chromatin structure of normal and leukemic lymphocytes. Cancer Res., 51: 470-473, 1992.
53. Traganos, F., Gong, J., Ardelt, B., and Darzynkiewicz, Z. Effect of Staurosporine on MOLT-4 cell progression through G2 and on cytokinesis. J. Cell. Physiol., 158: 535-544, 1994.
54. cdc24-like kinases. Biochem. Biophys. Res. Commun., 184: 80-85, 1992.
55. Park, D. J., Nakamura, H., Chumakov, A. M., Said, J. W., Miller, C. W., Chen, D. L., and Koeffler, H. P. Transactivational and DNA binding abilities of endogenous p53 in p53 mutant cell lines. Oncogene, 9: 1899-1906, 1994.
56. Jeoung, D. I., Tang, B., and Sonenberg, M. Induction of tumor suppressor p21 protein by kinase inhibitors in MCF-7 cells. Biochem. Biophys. Res. Commun., 214: 361-366, 1995.
57. Yang, Z-Y., Perkins, N. D., Ohno, T., Nabel, E. G., and Nabel, G. J. The p21 cyclin-dependent kinase inhibitor suppresses tumorigenicity in vivo. Nat. Med., 1: 1052-1056, 1995.
58. wAF1. Cancer Res., 55: 4536-4539, 1995.
59. Toyoshima, H., and Hunter, T. p27, a novel inhibitor of G1 cyclin-cdk protein kinase activity, is related to p21. Cell, 78: 67-74, 1994.
60. KIP1, J. Clin. Invest., 97: 1983-1988, 1996.